A Phase 4 interventional study of ZULRESSO® in Postpartum Depression, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 6 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Supernus Pharmaceuticals, Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.
Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 132nd largest by enrollment of the 198 interventional ones that give a count, is one of 13 that started in 2021, is one of 7 in phase 4, and was the 142nd registered.
569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.
Browse Depression, Postpartum studies →38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:
University of South Carolina · Sites in United States
Ages 18+ · Women only
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
University of Florida · Sites in United States
Ages 15–49 · Women only
Lipocine Inc. · Sites in United States
Ages 15–45 · Women only
Northwestern University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
220 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 20 · Phase 3 14 · Phase 4 7
First in 1996; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 104 across 454 interventional studies indexed under Depression, Postpartum.
Median enrollment 86 across the 198 interventional studies, 175 across the 22 observational. Of the 162 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 220 have an industry lead sponsor. The 10 most frequent:
Supernus Pharmaceuticals, Inc. is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
Supernus Pharmaceuticals, Inc. has 8 studies filed under Depression, Postpartum — fewer than ten, so there is no comparison to draw.
22 of the studies in Depression, Postpartum with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT07822321Phase 3Lipocine Inc.Brexanolone Lifting Outcomes Of Moms | 2027-08 |
| NCT05345834Children's National Research InstituteThe DC Mother-Infant Behavioral Wellness Program | 2026-11-30 |
| NCT06831968University of VirginiaClinical Validation of a Predictive Test for Postpartum Depression | 2026-11-30 |
| NCT06175104Children's Hospital Medical Center, CincinnatiHeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 220 studies in Depression, Postpartum with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study was to evaluate whether the safe-use conditions for administration of brexanolone (ZULRESSO®) can be implemented in a home setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant's home is suitable and has necessary provisions for administration of ZULRESSO® and meets the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a 60-hour single continuous intravenous (IV) infusion of ZULRESSO®, at 30 micrograms per kilogram per hour (mcg/kg/hour) (0 to 4 hours), at 60 mcg/kg/hour (4 to 24 hours), at 90 mcg/kg/hour (24 to 52 hours), followed by a dose taper to 60 mcg/kg/hour (52 to 56 hours), and 30 mcg/kg/hour (56 to 60 hours) during the study.
Drug: ZULRESSO®
Intravenous infusion of ZULRESSO®.
Also known as: Allopregnanolone, Brexanolone, SAGE-547
Percentage of Participants With At Least One Treatment-Emergent Adverse Event (TEAE) Leading to Dose Interruption/Discontinuation
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered with a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as an AE with onset after the start of investigational product, or any worsening of a preexisting medical condition/AE with onset after the start of investigational product and throughout the study. Percentages are rounded off to the nearest single decimal.
Time frame: Up to Day 3
Percentage of Participants With Nonadherence With the Safe-Use Conditions for Administration of ZULRESSO®
Nonadherence was defined by failure of any of following: * Home infusion provider to train all pharmacy and home healthcare providers (HHPs) in dispensing/administration of ZULRESSO® on risk of excessive sedation/loss of consciousness * HHPs to counsel participants on risk of excessive sedation/loss of consciousness * Deliver ZULRESSO® per protocol * Provide preprogrammed peristaltic pump * HHP:assess excessive sedation every 2 hours in planned nonsleep periods, change infusion bag per protocol, at least one HHP available in participant's home for the duration of infusion * Fall protocol in place * Monitor participants with pulse oximeter * Stop infusion when participant is primary caregiver of dependents and/or identification of excessive sedation/loss of consciousness/hypoxic episode * Caution participants post-infusion against engaging in hazardous activities requiring mental alertness * Complete AE of special interest/Serious AE form * Infusion resumed after hypoxia episode
Time frame: Up to Day 3
Number of Use-Related Issues Related to the Home Administration of ZULRESSO®
Home healthcare provider (HHP) staff completed checklists at end of each day and/or shift to document any use-related issues throughout duration of infusion. Any use-related issues determined to be critical in nature were followed up immediately and were reported adequately. Use-related issues were categorized as Critical Use Error (UE): HHP failed to complete a task or made uncorrected use error during task that could have resulted in harm, compromised medical care, incidence of nonadherence with safe use conditions for administration of ZULRESSO, or incidence of use-related issues related to home administration of ZULRESSO; Use Difficulty (UD): HHP successfully completed a task but did so while experiencing issues/operational difficulties; Close Call (CC): HHP committed error that could have led to a task failure, but self-corrected and completed task successfully. Multiple occurrences of issue throughout a single infusion was included only once in total.
Time frame: Up to Day 3
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAE was defined as an AE with onset after the start of investigational product, or any worsening of a preexisting medical condition/AE with onset after the start of investigational product and throughout the study. Percentages are rounded off to nearest single decimal.
Time frame: Up to Day 3
Percentage of Participants With Medication Error
Medication error was any preventable event that may cause or lead to inappropriate medication use or participant harm while the medication was in the control of the healthcare professional, participant, or consumer. Percentages are rounded off to the nearest single decimal.
Time frame: At screening and during the study (Up to Day 3)
Participants were enrolled at 5 active clinical sites in the United States from 08 October 2021 to 14 July 2022.
| Milestone | ZULRESSO® |
|---|---|
| Started | 52 |
| Treated | 42 |
| Completed | 42 |
| Not completed | 10 |
| Withdrew: Enrolled but not treated | 10 |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered with a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as an AE with onset after the start of investigational product, or any worsening of a preexisting medical condition/AE with onset after the start of investigational product and throughout the study. Percentages are rounded off to the nearest single decimal.
| percentage of participants | ZULRESSO® |
|---|---|
| Percentage of Participants With At Least One Treatment-Emergent Adverse Event (TEAE) Leading to Dose Interruption/Discontinuation | 7.1 |
Nonadherence was defined by failure of any of following: * Home infusion provider to train all pharmacy and home healthcare providers (HHPs) in dispensing/administration of ZULRESSO® on risk of excessive sedation/loss of consciousness * HHPs to counsel participants on risk of excessive sedation/loss of consciousness * Deliver ZULRESSO® per protocol * Provide preprogrammed peristaltic pump * HHP:assess excessive sedation every 2 hours in planned nonsleep periods, change infusion bag per protocol, at least one HHP available in participant's home for the duration of infusion * Fall protocol in place * Monitor participants with pulse oximeter * Stop infusion when participant is primary caregiver of dependents and/or identification of excessive sedation/loss of consciousness/hypoxic episode * Caution participants post-infusion against engaging in hazardous activities requiring mental alertness * Complete AE of special interest/Serious AE form * Infusion resumed after hypoxia episode
| percentage of participants | ZULRESSO® |
|---|---|
| Percentage of Participants With Nonadherence With the Safe-Use Conditions for Administration of ZULRESSO® | 76.19 |
Home healthcare provider (HHP) staff completed checklists at end of each day and/or shift to document any use-related issues throughout duration of infusion. Any use-related issues determined to be critical in nature were followed up immediately and were reported adequately. Use-related issues were categorized as Critical Use Error (UE): HHP failed to complete a task or made uncorrected use error during task that could have resulted in harm, compromised medical care, incidence of nonadherence with safe use conditions for administration of ZULRESSO, or incidence of use-related issues related to home administration of ZULRESSO; Use Difficulty (UD): HHP successfully completed a task but did so while experiencing issues/operational difficulties; Close Call (CC): HHP committed error that could have led to a task failure, but self-corrected and completed task successfully. Multiple occurrences of issue throughout a single infusion was included only once in total.
| Issues | ZULRESSO® |
|---|---|
| Critical Use Errors (UE) | 13 |
| Use Difficulties (UD) | 62 |
| Close Calls (CC) | 0 |
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAE was defined as an AE with onset after the start of investigational product, or any worsening of a preexisting medical condition/AE with onset after the start of investigational product and throughout the study. Percentages are rounded off to nearest single decimal.
| percentage of participants | ZULRESSO® |
|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | 42.9 |
Medication error was any preventable event that may cause or lead to inappropriate medication use or participant harm while the medication was in the control of the healthcare professional, participant, or consumer. Percentages are rounded off to the nearest single decimal.
| percentage of participants | ZULRESSO® |
|---|---|
| At Screening | 28.6 |
| During the Study (Up to Day 3) | 54.8 |
Collected over Up to Day 3. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZULRESSO® | 0/42 (0%) | 0/42 (0%) | 15/42 (35.7%) |
| Event | ZULRESSO® |
|---|---|
| FatigueGeneral disorders | 5/42 |
| HeadacheNervous system disorders | 4/42 |
| Infusion site painGeneral disorders | 3/42 |
| SomnolenceNervous system disorders | 3/42 |
Safety Set included all participants who were administered ZULRESSO®.
| Age, Continuous(years) | ZULRESSO® |
|---|---|
| Mean | 31.9 ± 5.76 |
| Sex: Female, Male(Participants) | ZULRESSO® |
|---|---|
| Female | 42 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | ZULRESSO® |
|---|---|
| Hispanic or Latino | 18 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | ZULRESSO® |
|---|---|
| White | 33 |
| Black or African American | 6 |
| Asian | 1 |
| American Indian or Alaska Native | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Other | 1 |
| Not Specified | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov
Ran from Oct 2021 to primary completion in Jul 2022, 9 months.
Results were first posted in Jul 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexanolone
Supernus Pharmaceuticals, Inc. →